Gilead Sciences, Inc. (NASDAQ:GILD) Receives $115.39 Average Price Target from Analysts

Key Points

• Gilead Sciences, Inc. has received an average rating of "Moderate Buy" from twenty-six analysts, with price targets averaging $115.39.
• The company reported $2.01 earnings per share, exceeding estimates and showing a 1.4% revenue increase compared to the previous year.
• Gilead recently announced a quarterly dividend of $0.79 per share, with a dividend yield of 2.7%, slated for payment on September 29th.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) has been given an average rating of "Moderate Buy" by the twenty-six research firms that are currently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation, seventeen have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $115.3913.

A number of equities analysts recently issued reports on GILD shares. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a research report on Tuesday, August 19th. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Royal Bank Of Canada lifted their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Finally, Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the stock from $108.00 to $127.00 in a research note on Friday, August 8th.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $296,325.00. Following the sale, the chief financial officer owned 160,110 shares in the company, valued at approximately $18,977,838.30. The trade was a 1.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the transaction, the director owned 8,920 shares in the company, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock worth $9,339,230 over the last 90 days. 0.27% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GILD. Rothschild Investment LLC boosted its holdings in Gilead Sciences by 1.9% during the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company's stock valued at $503,000 after acquiring an additional 84 shares during the period. Archer Investment Corp boosted its holdings in Gilead Sciences by 1.2% during the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company's stock valued at $807,000 after acquiring an additional 87 shares during the period. Binnacle Investments Inc boosted its holdings in Gilead Sciences by 14.3% during the second quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company's stock valued at $78,000 after acquiring an additional 88 shares during the period. EPG Wealth Management LLC boosted its holdings in Gilead Sciences by 2.0% during the second quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company's stock valued at $513,000 after acquiring an additional 89 shares during the period. Finally, Southland Equity Partners LLC boosted its holdings in Gilead Sciences by 2.9% during the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company's stock valued at $364,000 after acquiring an additional 92 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Performance

GILD stock traded down $0.62 on Friday, reaching $114.15. 3,776,361 shares of the company were exchanged, compared to its average volume of 8,253,455. Gilead Sciences has a 12 month low of $76.42 and a 12 month high of $121.83. The stock's fifty day moving average price is $112.51 and its 200 day moving average price is $109.16. The firm has a market capitalization of $141.64 billion, a PE ratio of 22.74, a PEG ratio of 0.70 and a beta of 0.33. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the firm posted $2.01 earnings per share. Gilead Sciences's revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts anticipate that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.